ImageneBio reports Q3 2026 results, reaffirms olevaprubart trial timelines

ImageneBio, Inc. (Nasdaq: IMA) reported financial results for the quarter ended September 30, 2026, on November 9, 2026, along with a company update.

The company said the Phase 2b ADAPTIVE trial and the long-term extension study of olevaprubart in moderate-to-severe atopic dermatitis continue to progress as planned.¹ Topline data from the ADAPTIVE study is anticipated in the fourth quarter of 2027.¹ The long-term extension study, which covers patients who finished one year of treatment in ADAPTIVE, also continues to progress as planned.¹

On the pipeline side, a Phase 2 study in alopecia areata is on track to initiate by the end of this year,¹ with initial data expected in 2028, drawing on clinical operations and investigator relationships built through the atopic dermatitis program and an earlier alopecia areata proof-of-concept trial.¹ The company also noted that no cases of Kaposi sarcoma have been observed to date across all clinical trials.¹

Imagene presented two posters on olevaprubart at the 2026 European Academy of Dermatology and Venereology Congress. In the alopecia areata proof-of-concept data, the company reported that hair- and follicle-related gene activity at the scalp recovered following treatment with olevaprubart, and that there were no statistically significant changes in peripheral or scalp measures of OX40 indicating depletion of OX40-positive cells, and no widespread immune function disruption, consistent with the drug's non-depleting design.¹

On finances, the company held $126.6 million in cash, cash equivalents and marketable securities as of September 30, 2026¹, which it said is enough to fund planned operations into the first quarter of 2028.¹ R&D expenses were $11.3 million versus $15.2 million a year earlier, G&A expenses were $6.0 million versus $11.0 million, and net loss was $15.6 million versus $24.8 million for the same period in 2025.¹